Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the ...

This was the stock's third consecutive day of losses.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and General Motors among those reporting.

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...